Physician profile
Marshall Kamer
NPI 1588684336
$824.51
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $210 · 2021: $47.55 · 2022: $11.71 · 2024: $17.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $286.17 | 2019-2020 | |
| Janssen Biotech, INC. | $100.92 | 2019-2021 | |
| Rochester Medical Corporation | $72.26 | 2019-2022 | |
| Pfizer INC. | $59.73 | 2019 | |
| Amgen INC. | $48.09 | 2019-2020 | |
| Coloplast Corp | $43.54 | 2019-2020 | |
| Blue Earth Diagnostics | $40.87 | 2019-2020 | |
| Baxter Healthcare | $26.92 | 2019 | |
| Neotract INC. | $19.94 | 2020 | |
| Abbvie INC. | $17.97 | 2024 | |
| Travere Therapeutics, INC. | $17.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.32 | 2020 | |
| Endo Pharmaceuticals INC. | $15.89 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.38 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $13.48 | 2019 | |
| Allergan, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Kamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.